Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. (Q39611397)

From Wikidata

Jump to navigation Jump to search

scientific article published on 5 January 2011

Language	Label	Description	Also known as
English	Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.	scientific article published on 5 January 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21211830%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21211830%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Donald J Buchsbaum

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21211830%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Kerri S Bevis

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21211830%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Lacey R McNally

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21211830%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Jeffery C Sellers

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21211830%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Deborah Della Manna

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21211830%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Angelina Londoño Joshi

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21211830%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Hope Amm

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21211830%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

J Michael Straughn

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21211830%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

language of work or name

0 references

publication date

5 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21211830%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21211830%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

121

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21211830%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21211830%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

193-199

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21211830%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Recurrent ovarian cancer: how important is it to treat to disease progression?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

A novel receptor for Apo2L/TRAIL contains a truncated death domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

The receptor for the cytotoxic ligand TRAIL

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.046

7 January 2021

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39611397&oldid=1473856874"